Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NX-2127 · 1 trial · 8 indications
Phase 1a
Phase 1a
Phase 1b
Phase 1a/1b
| Arm | Type | Description |
|---|---|---|
| Phase 1a Dose Escalation | EXPERIMENTAL | Multiple dose levels of NX-2127 to be evaluated; determination of MTD/Phase 1b recommended dose |
| Phase 1b Dose Optimization Stage 1 in CLL or SLL (Dose A) | EXPERIMENTAL | CLL/SLL patients whose disease has failed treatment with a BTK inhibitor |
| Phase 1b Dose Optimization Stage 1 in MCL (Dose A) | EXPERIMENTAL | MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen |
| Phase 1b Dose Optimization Stage 1 in FL, MZL or WM (Dose A) | EXPERIMENTAL | FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTK inhibitor |
| Phase 1b Dose Optimization Stage 1 in DLBCL (Dose A) | EXPERIMENTAL | DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen; or another/palliative regimen |
| Phase 1b Dose Optimization Stage 1 in PCNSL (Dose A) | EXPERIMENTAL | PCNSL patients whose disease has failed at least 1 prior line of treatment |
| Phase 1b Dose Optimization Stage 2 in CLL or SLL (Randomized to Dose A or Dose B) | EXPERIMENTAL | CLL/SLL patients whose disease has failed treatment with a BTK inhibitor |
| Phase 1b Dose Optimization Stage 2 in MCL (Randomized to Dose A or Dose B) | EXPERIMENTAL | MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen |
| Phase 1b Dose Optimization Stage 2 in FL, MZL or WM (Randomized to Dose A or Dose B) | EXPERIMENTAL | FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTK inhibitor |
| Phase 1b Dose Optimization Stage 2 in DLBCL (Randomized to Dose A or Dose B) | EXPERIMENTAL | DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen; or another/palliative regimen |
| Phase 1b Dose Optimization Stage 2 in PCNSL (Randomized to Dose A or Dose B) | EXPERIMENTAL | PCNSL patients whose disease has failed at least 1 prior line of treatment |
| Name | Type | Description |
|---|---|---|
| NX-2127 | DRUG | Oral NX-2127 |
Inclusion Criteria: * Patients must be ≥ 18 years of age * Patients must have measurable disease per disease-specific response criteria * Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, o...
NX-2127 is an investigational small molecule being studied for the treatment of Chronic Lymphocytic Leukemia (CLL). It is currently in Phase 1 clinical development, and the ongoing trial also includes patients with other B-cell malignancies such as Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, and others.
NX-2127 targets BTK, a protein involved in B-cell receptor signaling. By targeting BTK, NX-2127 is designed to interfere with pathways that support the survival and proliferation of malignant B-cells, which is relevant in diseases like Chronic Lymphocytic Leukemia.
NX-2127 is being developed by Nurix Therapeutics, Inc., a biopharmaceutical company. Nurix Therapeutics is publicly traded under the ticker symbol NRIX on the NASDAQ stock exchange.
NX-2127 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial is currently recruiting participants to evaluate the safety and efficacy of NX-2127 in adults with relapsed or refractory B-cell malignancies.
NX-2127 is being evaluated in a Phase 1 clinical trial with the identifier NCT04830137. This study is titled 'A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies' and is currently recruiting participants in the United States. The trial is designed to enroll approximately 248 patients.
NX-2127 is a distinct investigational BTK-targeting agent developed by Nurix Therapeutics. While it shares the same molecular target as other BTK inhibitors, NX-2127 is a unique small molecule with its own chemical structure and is being studied specifically in the context of relapsed or refractory B-cell malignancies.